The spinout has bagged support from Inserm Transfert Initiative and two Bpifrance-managed funds for its clinical-stage therapy for hepatitis B.

Enyo Pharma, a France-based viral infection therapy developer spun out from Claude Bernard Lyon 1 University, closed a €40m ($46.8m) series B round yesterday featuring Inserm Transfert Initiative, the early-stage investment fund of research institute Inserm.

The round was led by healthcare-focused investment firm Orbimed Advisors and also featured Innobio and Bpifrance Large Venture, two funds managed by French government-owned investment bank Bpifrance.

Sofinnova Private Capital VII, Andera Partners and Morningside Venture Investments also provided funding.

Founded in 2014, Enyo…